Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer

• Asıl Yazarlar: Xueyan Liang (Yazar), Xiaoyu Chen (Yazar), Huijuan Li (Yazar), Yan Li (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background and objectiveTislelizumab is a programmed cell death protein-1 (PD-1) inhibitor. Tislelizumab plus chemotherapy as first-line option for advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy alone, resulted in significantly prolonged survival outcomes; howev...